HRP20050174A2 - Thiomolybdate analogues and uses thereof - Google Patents

Thiomolybdate analogues and uses thereof Download PDF

Info

Publication number
HRP20050174A2
HRP20050174A2 HR20050174A HRP20050174A HRP20050174A2 HR P20050174 A2 HRP20050174 A2 HR P20050174A2 HR 20050174 A HR20050174 A HR 20050174A HR P20050174 A HRP20050174 A HR P20050174A HR P20050174 A2 HRP20050174 A2 HR P20050174A2
Authority
HR
Croatia
Prior art keywords
substituted
elements
substances according
substance
patient
Prior art date
Application number
HR20050174A
Other languages
English (en)
Croatian (hr)
Inventor
Robert
Mazar Andrew
Patricia
Coucouvanis Dimitri
Amy
Sean
Mellissa
Steven
Donate Fernando
Original Assignee
The Regents of the University of Michigan Attenuon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/202,346 external-priority patent/US20040019043A1/en
Application filed by The Regents of the University of Michigan Attenuon filed Critical The Regents of the University of Michigan Attenuon
Publication of HRP20050174A2 publication Critical patent/HRP20050174A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/64—Quaternary ammonium compounds having quaternised nitrogen atoms bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20050174A 2002-07-23 2003-07-22 Thiomolybdate analogues and uses thereof HRP20050174A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/202,346 US20040019043A1 (en) 2002-07-23 2002-07-23 Thiomolybdate analogues and uses thereof
US43474202P 2002-12-18 2002-12-18
US43695803A 2003-05-12 2003-05-12
US10/447,585 US7189865B2 (en) 2002-07-23 2003-05-28 Thiomolybdate analogues and uses thereof
PCT/US2003/023031 WO2004009034A2 (en) 2002-07-23 2003-07-22 Thiomolybdate analogues and uses thereof

Publications (1)

Publication Number Publication Date
HRP20050174A2 true HRP20050174A2 (en) 2005-10-31

Family

ID=30773643

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050174A HRP20050174A2 (en) 2002-07-23 2003-07-22 Thiomolybdate analogues and uses thereof

Country Status (19)

Country Link
US (1) US7189865B2 (de)
EP (1) EP1556029B1 (de)
JP (1) JP2006506466A (de)
KR (1) KR20050053596A (de)
CN (1) CN100531732C (de)
AU (1) AU2003256704A1 (de)
BR (1) BR0312851A (de)
CA (1) CA2493127A1 (de)
DK (1) DK1556029T3 (de)
EA (1) EA200500250A1 (de)
ES (1) ES2448800T3 (de)
HR (1) HRP20050174A2 (de)
IL (1) IL166448A0 (de)
MX (1) MXPA05000870A (de)
NO (1) NO20050917L (de)
PL (1) PL374821A1 (de)
PT (1) PT1556029E (de)
SI (1) SI1556029T1 (de)
WO (1) WO2004009034A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (zh) * 1998-09-25 2001-11-28 格利科克斯有限公司 果糖胺氧化酶,拮抗剂和抑制剂
US7312244B2 (en) * 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
IL146127A0 (en) * 1999-04-30 2002-07-25 Slil Biomedical Corp Conformationally restricted polymine analogs as disease therapies
WO2000066175A2 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
WO2003018595A2 (en) * 2001-08-24 2003-03-06 Maine Medical Center Research Institute Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
EP1436246A1 (de) * 2001-10-16 2004-07-14 SLIL Biomedical Corporation Oligoamin-verbindungen und ihre derivate für die krebstherapie
ES2386782T3 (es) * 2002-03-08 2012-08-30 Philera New Zealand Limited Prevención y/o tratamiento de la enfermedad cardiovascular y/o la insuficiencia cardíaca asociada
CA2490541A1 (en) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
CA2493341A1 (en) * 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
CA2875522A1 (en) 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
ZA200509719B (en) * 2003-05-27 2007-03-28 Attenuon Llc Thiotungstate analogues and uses thereof
WO2005082382A1 (en) * 2004-02-23 2005-09-09 Attenuon Llc Formulations of thiomolybdate or thiotungstate compounds and uses thereof
EP1721010A2 (de) * 2004-02-24 2006-11-15 Attenuon, LLC Hemmung der superoxiddismutase durch tetrathiomolybdate: identifizierung neuen anti-angiogenisch- und antitumormittel
EP1778618B1 (de) 2004-07-19 2013-12-25 PhilERA New Zealand Limited Synthese von triethylenetetraminen
JP5099620B2 (ja) * 2006-10-26 2012-12-19 学校法人日本大学 筋萎縮性側索硬化症治療薬
US7893289B2 (en) * 2007-02-21 2011-02-22 Ssv Therapeutics, Inc. Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
US20090028800A1 (en) * 2007-07-27 2009-01-29 Peeples William H Method of Treating Postpartum Depression and Aggression
EP2803356A1 (de) * 2008-03-31 2014-11-19 Agency for Science, Technology and Research Verfahren zur Behandlung neurologischer Erkrankungen mit Imidazolium und Imidazoliniumverbindungen
JP6285164B2 (ja) * 2013-12-05 2018-02-28 デクセリアルズ株式会社 化合物、熱硬化性樹脂組成物、及び熱硬化性シート
AU2017223196B2 (en) * 2016-02-23 2020-05-14 Vanderbilt Chemicals, Llc Quaternary ammonium sulfur-containing binuclear molybdate salts as lubricant additives
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
KR102803161B1 (ko) 2017-12-04 2025-05-07 알렉시온 파마 인터내셔널 오퍼레이션즈 리미티드 윌슨병을 치료하기 위한 비스-콜린 테트라티오몰리브데이트
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate
EP3752482B1 (de) * 2018-02-15 2023-08-16 Alexion Pharma International Operations Unlimited Company Verfahren zur herstellung von bis-cholin-tetrathiomolybdat
WO2020148654A2 (en) 2019-01-14 2020-07-23 Alexion Pharma International Operations Unlimited Company Methods for preparing ammonium tetrathiomolybdate
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4225386B1 (de) 2020-10-07 2024-10-30 CTI Vascular AG Bioaktivierbare vorrichtungen und zugehörige verfahren
WO2022165339A1 (en) * 2021-01-31 2022-08-04 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
US20230226105A1 (en) * 2021-11-10 2023-07-20 Reverspah Llc Methods and compositions for treating cancer
CN114042083B (zh) * 2021-12-06 2022-08-30 湖南师范大学 四硫代钼酸盐的增肌及治疗应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) * 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4400282A (en) 1980-12-05 1983-08-23 Gulf Research & Development Company Lubricating oils containing quaternary ammonium thiomolybdates
US4343746A (en) * 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4430443A (en) * 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
AU690438B2 (en) * 1995-03-14 1998-04-23 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
DE69621604T2 (de) * 1995-03-14 2002-11-28 Siemens Ag Ultraschall-zerstäuber mit abnehmbarer präzisionsdosiereinheit
WO1999020374A1 (en) 1997-10-17 1999-04-29 Ebara Corporation Method and apparatus for processing exhaust gas of semiconductor fabrication
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
ES2188261T3 (es) * 1998-09-04 2003-06-16 Univ Michigan Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides.
CN1262226A (zh) 1999-12-03 2000-08-09 中国科学院兰州化学物理研究所 硫代钼酸盐及其制备方法和用途
CA2490541A1 (en) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
CA2493341A1 (en) * 2002-07-23 2004-01-29 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

Also Published As

Publication number Publication date
CN100531732C (zh) 2009-08-26
EP1556029A4 (de) 2008-06-25
JP2006506466A (ja) 2006-02-23
KR20050053596A (ko) 2005-06-08
BR0312851A (pt) 2005-07-12
WO2004009034A2 (en) 2004-01-29
EA200500250A1 (ru) 2005-12-29
PT1556029E (pt) 2014-03-04
US7189865B2 (en) 2007-03-13
EP1556029B1 (de) 2013-11-27
CA2493127A1 (en) 2004-01-29
AU2003256704A1 (en) 2004-02-09
ES2448800T3 (es) 2014-03-17
SI1556029T1 (sl) 2014-06-30
US20040019087A1 (en) 2004-01-29
DK1556029T3 (en) 2014-03-10
PL374821A1 (en) 2005-10-31
CN1684678A (zh) 2005-10-19
IL166448A0 (en) 2006-01-15
MXPA05000870A (es) 2005-08-29
EP1556029A2 (de) 2005-07-27
WO2004009034A3 (en) 2004-09-10
NO20050917L (no) 2005-04-20

Similar Documents

Publication Publication Date Title
ES2448800T3 (es) Sales de tiomolibdato y sus usos
US20110151022A1 (en) Thiotungstate analogues and uses thereof
AU2009253797B2 (en) N-piperidinyl acetamide derivatives as calcium channel blockers
DK2356109T3 (en) COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES
KR19990081823A (ko) 카파 길항제 화합물 및 이들의 약제학적 제형
JP2018517672A (ja) イソオキサゾリル置換イミダゾピリジン類
CN115417877B (zh) 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用
CN112174945B (zh) 具有抗癌作用的吲唑类化合物及其制备方法和用途
CN110753691B (zh) 用于治疗性和/或预防性治疗癌症的化合物
CN110573147B (zh) 用于抑制癌症转移的包含nm23活化剂的药物组合物
JP5330377B2 (ja) ３，４−ジヒドロキナゾリン誘導体
US20040019043A1 (en) Thiomolybdate analogues and uses thereof
JP2004527583A (ja) ディスコデルモライド酸のある種の塩、それらを含有する医薬組成物および腫瘍の処置におけるそれらの使用
CN117693517A (zh) 用于靶向治疗肾癌的新型化合物和组合物
CN111233809A (zh) 一种Millepachine-CA-4衍生物及其制备方法和应用
AU2006210627B2 (en) Acid addition salts of Ac-PHSCN-NH2
TW200538107A (en) Thiotungstate analogues and uses thereof
HK40022857A (en) Compounds for use in the therapeutic and/or prophylactic treatment of cancer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080722

Year of fee payment: 6

PNAN Change of the applicant name, address/residence

Owner name: ATTENUON, LLC., US

OBST Application withdrawn